HtrA1 as a promising tissue marker in cancer: a meta-analysis

Abstract

BackgroundHtrA1 is expressed in a variety of normal human tissues and seems to be involved in numerous physiological processes as well as tumorigenesis. This study reports the results of a meta-analysis that was performed: to compare HtrA1 expression as mRNA and protein, in cancer tissue versus non-cancer tissue and to assess overall survival in relation to low or medium-high HtrA1 tissue expression.MethodsThe PRISMA method was used for study selection. OR and HR with 95% confidence interval was used as a measure of effect size as appropriate. A random-effects model was applied to account for different sources of variation among studies. Heterogeneity across studies was assessed using Q statistic. Sensitivity analysis was conducted to check the stability of study findings. Egger’s regression method was applied to test funnel plot asymmetry.ResultsSensitivity analysis indicated the stability of meta-analytic findings in each meta-analysis. The study found a significantly different HtrA1 expression in cancer and non-cancer tissue. The meta-analysis of the prognostic studies showed a different survival according to HtrA1 expression.ConclusionsThe present data may provide a contribution to future work directed at exploring the role of HtrA1 in tumor development and progression and at establishing whether it may be used as a promising tissue marker for some tumors.Electronic supplementary materialThe online version of this article (10.1186/s12885-018-4041-2) contains supplementary material, which is available to authorized users.

Effect of HtrA1 Polymorphism on Sensitivity to Chemotherapy in Patients with Colon Cancer

“…HtrA1 belongs to the serine protease family, and its deficient expression has been reported in several human cancers, such as pancreatic cancer [20], breast cancer [21], and hepatocellular carcinoma [22]. HtrA1 can suppress malignant development and progression of cancer [23], and it also has been reported to be involved in chemotherapy resistance. For example, Xu et al reported that loss of HtrA1 expression can induce cancer stem cell-like properties of lung adenocarcinoma cells, leading to resistance to cisplatin treatment [24].…”

Insufficient HtrA2 causes meiotic defects by inducing cytoskeletal disorganization in aging germinal vesicle oocytes

“…HtrA2 is located in the mitochondrial intermembrane space where it contributes to mitochondrial homeostasis and protects against cellular stress under normal physiological conditions [11,12]. Once apoptosis is triggered, HtrA2 is released into the cytosol, where it binds to and degrades apoptotic factors, such as XIAP and CIAP1/2 [13][14][15][16].…”

Insufficient HtrA2 causes meiotic defects in aging germinal vesicle oocytes

“…HtrA2, which does not contain such a domain, participates in cell apoptosis to ensure the physiological turnover of trophoblasts and in this way affects pregnancy outcome [8][9][10]. HtrA2 is located in the mitochondrial intermembrane space where it contributes to mitochondrial homeostasis and protects against cellular stress under normal physiological conditions [11,12]. Once apoptosis is triggered, HtrA2 is released into the cytosol, where it binds to and degrades apoptotic factors, such as XIAP and CIAP1/2 [13][14][15][16].…”